Grant's research team sought to develop a strategy to prevent the accumulation of MCL-1 in leukemia cells through a clinically effective treatment option. Building upon decades of their earlier ...

From new KRAS and HER2 inhibitors to home-administered immunotherapy, recent trials mark a turning point in how metastatic lung cancer is managed.

The clinical trial experience of combination therapy is limited and the optimal combinations and administration strategies have yet to be clarified.

Adding immunotherapy to new KRAS inhibitors boosted responses in preclinical models, setting the stage for future trials of the combination strategy. Adding immunotherapy to a new type of ...

The combination not only killed the leukemia ... has now investigated a new strategy. STAT3 exists in two isoforms: STAT3α ...